Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Albain, Kathy S ^a,b   Paik, Soonmyung ^c   van't Veer, Laura ^d  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^c NSABP Foundation Inc   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Adjuvant therapy; Chemotherapy prediction; Early breast cancer; Multigene assays

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FROZEN SECTION; GENETIC ANALYSIS; HISTOPATHOLOGY; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL LITERATURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 71749091235     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70290-5     Document Type: Article

References (38)

1. Dowsett M., Goldhirsch A., Hayes D.F., Senn H.J., Wood W., and Viale G. International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9 6 (2007) R81
2. van't Veer L.J., Paik S., and Hayes D.F. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 23 8 (2005) 1631-1635
3. Sotiriou C., and Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 360 (2009) 790-800
4. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
5. Habel L.A., Shak S., Jacobs M.K., Capra A., Alexander C., Pho M., et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Research 8 3 (2006) R25
6. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 247 (2002) 1999-2009
7. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
8. Sotiriou C., Wirapati P., Loi S., et al. Expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
9. Ma X.J., Hilsenbeck S.G., Wang W., et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24 (2006) 4611-4619
10. Ma X.J., Salunga R., Dahiya S., et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14 (2008) 2601-2608
11. Wang Y., Klijn K., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
12. Chang H.Y., Nuyten D.S., Sneddon J.B., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102 (2005) 3738-3743
13. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356 (2007) 217-226
14. Naderi A., Teschendorff A.E., Barbosa-Morais N.L., et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26 (2007) 1507-1516
15. Teschendorff A.E., Naderi A., Barbosa-Morais N.L., et al. A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol 7 (2006) R101
16. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102 (2005) 1350-1355
17. Glinsky G.V., Berezovska O., and Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115 (2005) 1503-1521
18. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
19. Goldhirsch A., Wood W.C., Gelber R.D., et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
20. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 33 (2007) 5287-5312
21. NCCN Practice Guidelines in Oncology. Invasive Breast Cancer. www.NCCN.org, v.2.2008.
22. Albain K., Barlow W., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). Breast Cancer Res Treat 106 Suppl 1 (2007) #10
23. Mook S., Schmidt M.K., Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat (2008) [Epub July 27].
24. Knauer M., Straver M., Rutgers E., et al. The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer. Breast 18 Suppl 1 (2009) S36 (abstract 73).
25. Castiglione-Gertsch M., Price K.N., Goldhirsch A., et al. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial of the International Breast Cancer Study Group (Trial IX). J Natl Cancer Inst 994 (2002) 1054-1065
26. Fisher B., Jeong J.-H., Bryant J., et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings form National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet 364 (2004) 858-868
27. Albain K., Barlow W., O'Malley F., et al. Concurrent versus sequential chemohormonal therapy versus tamoxifen alone for postmenopausal, node-positive, ER and/or PgR-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (S8814). Breast Cancer Res Treat 90 (2005) 195
28. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365 (2005) 1687-1717
29. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
30. Bueno de Mesquita J.M., Linn S.C., Keijzer R., et al. Validation of the 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) (published online September 26).
31. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
32. Straver M.E., Glas A.M., Hannemann J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2009) (published online February 13).
33. Oratz R., Paul D., Cohn A.L., and Sedlacek S.M. Impact of a commercial reference laboratory test reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Practice 3 (2007) 182-186
34. Kamal A.H., Loprinzi C.L., Reynolds C., Dueck A.C., Geiger X.J., Ingle L.N., et al. How well do standard prognostic criteria predict Oncotype Dx scores?. J Clin Oncol 25 18S (2007) #576
35. Lo SS, Mumby PB, Rychlik K, Smerage J, Kash J, Chew HK, et al. Extended followup results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction and anxiety. J Clin Oncol 2009; in press.
36. Asad J., Jacobson A.F., Estabrook A., et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer?. Am J Surg 196 (2008) 527-529
37. Bueno de Mesquita J.M., van Harten W.H., Retel V.P., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a community-based feasibility study (RASTER). Lancet Oncol 8 (2007) 1079-1087 Erratum:
38. Bueno de Mesquita J.M., van Harten W.H., Retel V.P., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a community-based feasibility study (RASTER). Lancet Oncol 9 (2008) 10